142 related articles for article (PubMed ID: 35506073)
1. Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension.
Tamura Y; Furukawa A; Tamura Y; Yamada K; Taniguchi H; Fukuda K; Kawamura A; Satoh T
Pulm Circ; 2022 Jan; 12(1):e12058. PubMed ID: 35506073
[TBL] [Abstract][Full Text] [Related]
2. Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag.
Hinkamp C; Bartolome S; Mims E; Chin K; Shah T
Biomed Hub; 2022; 7(3):115-124. PubMed ID: 36465803
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
4. Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension.
Pan IZ; Carey JR; Jacobs JA; Dechand J; Sessions JJ; Sorensen T; Penn BA; Mayeux JD; Hatton ND; Ryan JJ
Front Med (Lausanne); 2020; 7():81. PubMed ID: 32296704
[No Abstract] [Full Text] [Related]
5. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension.
Colglazier E; Ng AJ; Parker C; Nawaytou H; Fineman JR
J Pediatr Pharmacol Ther; 2021; 26(5):512-516. PubMed ID: 34239406
[TBL] [Abstract][Full Text] [Related]
7. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
8. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
9. An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension.
Oudiz R; Agarwal M; Rischard F; De Marco T
Pulm Circ; 2016 Dec; 6(4):532-538. PubMed ID: 28090295
[TBL] [Abstract][Full Text] [Related]
10. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
[No Abstract] [Full Text] [Related]
11. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
12. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
Diaz-Guzman E; Heresi GA; Dweik RA; Minai OA
Respir Med; 2008 May; 102(5):681-9. PubMed ID: 18280130
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
[TBL] [Abstract][Full Text] [Related]
14. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
[TBL] [Abstract][Full Text] [Related]
15. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
16. Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients.
Aldweib N; Verlinden NJ; Kassis-George H; Raina A
Pulm Circ; 2021; 11(4):20458940211036623. PubMed ID: 34646497
[TBL] [Abstract][Full Text] [Related]
17. Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report.
Rossi S; Pietrangelo C; Pierdomenico SD; Giuliani L
Eur Heart J Case Rep; 2020 Oct; 4(5):1-5. PubMed ID: 33204960
[TBL] [Abstract][Full Text] [Related]
18. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Verlinden NJ; Walter C; Raina A; Benza RL
J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
[TBL] [Abstract][Full Text] [Related]
19. Transition from epoprostenol to selexipag in a patient with systemic sclerosis and pulmonary hypertension during the postoperative period of colon cancer surgery: A case report.
Wada TT; Yokota K; Iida S; Kanno Y; Shinozuka N; Sato K; Asanuma YF; Yamamoto K; Mimura T
J Scleroderma Relat Disord; 2022 Jun; 7(2):NP4-NP8. PubMed ID: 35585949
[TBL] [Abstract][Full Text] [Related]
20. Selexipag for the treatment of pulmonary arterial hypertension.
Genecand L; Wacker J; Beghetti M; Lador F
Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
